Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 4,152 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,152 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the completion of the transaction, the insider now owns 157,345 shares in the company, valued at $9,549,268.05. This trade represents a 2.57 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Soleil Boughton also recently made the following trade(s):

• On Monday, February 3rd, Soleil Boughton sold 4,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.30, for a total value of $146,600.90.
• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total value of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.90, for a total value of $70,055.70.

Hims & Hers Health Stock Down 3.6 %

Hims & Hers Health stock traded down $2.46 during mid-day trading on Thursday, hitting $66.28. 30,711,275 shares of the company’s stock were exchanged, compared to its average volume of 15,817,041. The firm has a market capitalization of $14.48 billion, a P/E ratio of 150.64 and a beta of 1.35. Hims & Hers Health, Inc. has a fifty-two week low of $9.22 and a fifty-two week high of $72.98. The company’s 50 day simple moving average is $33.94 and its 200-day simple moving average is $25.19.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently added to or reduced their stakes in the business. Mackenzie Financial Corp increased its holdings in Hims & Hers Health by 44.6% during the 4th quarter. Mackenzie Financial Corp now owns 29,096 shares of the company’s stock worth $704,000 after purchasing an additional 8,977 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in shares of Hims & Hers Health in the 4th quarter valued at about $99,000. Neo Ivy Capital Management grew its holdings in Hims & Hers Health by 145.4% during the fourth quarter. Neo Ivy Capital Management now owns 166,734 shares of the company’s stock worth $4,031,000 after purchasing an additional 98,798 shares during the period. PharVision Advisers LLC bought a new position in Hims & Hers Health during the fourth quarter worth about $234,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Hims & Hers Health by 31.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,156 shares of the company’s stock worth $8,225,000 after purchasing an additional 81,495 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the subject of several recent research reports. TD Cowen reaffirmed a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upped their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Citigroup lowered Hims & Hers Health from a “neutral” rating to a “sell” rating and increased their price target for the stock from $24.00 to $25.00 in a research report on Friday, January 10th. Needham & Company LLC increased their price objective on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Finally, Canaccord Genuity Group increased their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.53.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.